Stock 0TDF ROCHE HOLDING AG
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Roche Holding AG London S.E.

Equities

0TDF

US7711951043

Market Closed - London S.E.
Other stock markets
 07:01:49 12/06/2024 pm IST 		5-day change 1st Jan Change
34.01 USD +7.19% Intraday chart for Roche Holding AG -4.17% -5.26%
28/06 Swiss Market Index Closes Little Changed Amid Key European Inflation Data MT
28/06 Roche's Eye Therapy Vabysmo Gets EU Panel's Nod for Additional Indication MT

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Swiss Market Index Closes Little Changed Amid Key European Inflation Data
MT
Roche's Eye Therapy Vabysmo Gets EU Panel's Nod for Additional Indication
MT
Roche Gets EU Panel's Backing for Rare Blood Disorder Therapy
MT
Roche's Vabysmo Wins EMA Panel's Backing for Retinal Vein Occlusion Indication
MT
Roche's Rare Blood Disorder Drug PiaSky Backed for Approval in EU
MT
EMA Says CHMP Gave Positive Opinion For mResvia RSV mRNA Vaccine For Prevention In Adults 60 Years And Older
RE
Roche Receives Additional Prequalification Designations for HPV Test
MT
Roche Wins EU Nod for Subcutaneous Formula of Multiple Sclerosis Drug Ocrevus
MT
Halozyme Therapeutics, Inc. Announces Roche's OCREVUS SC with ENHANZE Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis
CI
Roche Announces the European Commission Grants Marketing Authorisation for OCREVUS (Ocrelizumab) Subcutaneous for the Treatment of Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis
CI
Global markets live: Novo Nordisk, Apple, UPS, Eli Lilly, Qualcomm...
Our Logo
Foreign banks target Switzerland after UBS takeover of Credit Suisse
RE
Roche: two new units for cobas pro
CF
European Medicines Agency Begins Review of Roche's Gene Therapy for Duchenne Muscular Dystrophy
MT
US FDA approves Roche's drug for a chronic blood disorder
RE
Sarepta Therapeutics Gets Expanded Label FDA Approval for Duchenne Muscular Dystrophy; Shares Soar Premarket
MT
Sarepta Therapeutics Gets Expanded US FDA Approval for Treatment of Duchenne Muscular Dystrophy; Shares Soar After Hours
MT
US FDA approves expanded use of Sarepta's Duchenne gene therapy; shares jump
RE
Sarepta Shares Soar 37% Following Expanded Approval for Elevidys
DJ
Sarepta Therapeutics, Inc. Announces Expanded US FDA Approval of Eletidys to Duchenne Muscular Dystrophy Patients Ages 4 and Above
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ROG Stock
  4. 0TDF Stock
  5. News Roche Holding AG
  6. Highlights